HER2 — Drug Target

All drugs that target HER2 — marketed and clinical-stage. Includes 6 drug classes acting on this target.

Drug classes

Endoglycosidase [EPC] · HER2 tyrosine kinase inhibitor · HER2/neu receptor antagonist · Antibody-drug conjugate (ADC) · HER2-targeting antibody-drug conjugate · HER2 inhibitor

Marketed (1)

• Trastuzumab and Hyaluronidase-oysk · Adrienne G. Waks · Endoglycosidase [EPC]
  Trastuzumab inhibits HER2-overexpressing tumor cell proliferation and mediates ADCC, while hyaluronidase increases subcutaneous permeability for better drug absorption.

Phase 3 pipeline (5)

• Pimicotinib(ABSK021) · Abbisko Therapeutics Co, Ltd · HER2 tyrosine kinase inhibitor · Oncology
  Pimicotinib is a tyrosine kinase inhibitor that targets HER2 (human epidermal growth factor receptor 2) to inhibit cancer cell growth and proliferation.
• Trastuzumab-EU · Pfizer · HER2/neu receptor antagonist · Oncology
  Trastuzumab-EU is a monoclonal antibody that targets the HER2/neu receptor.
• ABP 980 · Amgen · Antibody-drug conjugate (ADC) · Oncology
  ABP 980 is a HER2-targeting antibody-drug conjugate that delivers cytotoxic payload to HER2-expressing cancer cells.
• trastuzumab deruxtecan (T-DXd) · GI Innovation, Inc. · HER2-targeting antibody-drug conjugate · Oncology
  Trastuzumab deruxtecan (T-DXd) is a HER2-targeting antibody-drug conjugate that delivers a DNA crosslinking agent to cancer cells.
• Trastuzumab Emtansine for Injection · Shanghai Miracogen Inc. · HER2-targeting antibody-drug conjugate · Oncology
  Trastuzumab emtansine targets the HER2 protein on cancer cells and delivers a toxic payload to kill them.

Phase 2 pipeline (3)

• Breast cancer cohort · Centre Leon Berard · HER2 inhibitor · Oncology
  This drug targets the HER2 protein to inhibit cancer cell growth.
• Ado-trastuzumab emtamsine · Hoffmann-La Roche · HER2-targeting antibody-drug conjugate · Oncology
  Ado-trastuzumab emtansine is a HER2-targeting antibody-drug conjugate that delivers a cytotoxic agent to HER2-positive cancer cells.
• HKI-272 · Puma Biotechnology, Inc. · HER2 inhibitor · Oncology
  HKI-272 is a small molecule inhibitor of the human epidermal growth factor receptor 2 (HER2) tyrosine kinase.

Phase 1 pipeline (1)

• ARRY-380, HER2 inhibitor; oral · Seagen Inc. · HER2 inhibitor · Oncology
  HER2 inhibitor